CXCR4 and retinoblastoma: This triple approach of pH-activated cytotoxic nanoceria, the CXCR4 antagonist and the traditional chemotherapeutic agent, doxorubicin, demonstrated a synergistic effectiveness against retinoblastoma, both in vitro and in vivo [32].